Experimental CAR t cell cocktail takes on recurrent glioblastoma
NCT ID NCT04003649
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests whether a special type of immune cell (CAR T cell) that targets a protein found on glioblastoma cells can be safely given along with two immunotherapy drugs (nivolumab and ipilimumab). The study involves 20 adults with recurrent or treatment-resistant glioblastoma. The main goals are to check for side effects and see if the treatment is feasible before and after surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IL13Rα2-targeted CAR T cells (a type of immune cell therapy) combined with nivolumab and ipilimumab (immunotherapy drugs)
What this could lead to
If successful, this could point toward a new treatment option for recurrent glioblastoma, a brain cancer with very few effective therapies.
What could go wrong
This is a very early (phase 1) and small trial (20 people), focused mainly on safety. The combination may cause serious side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States